vs
Side-by-side financial comparison of Allstate (ALL) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Allstate is the larger business by last-quarter revenue ($922.0M vs $708.5M, roughly 1.3× Medpace Holdings, Inc.). Allstate runs the higher net margin — 266.6% vs 19.1%, a 247.5% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 7.2%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -75.8%).
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. The company operates through Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability segments. The Allstate Protection segment offers private passenger auto and homeowners insurance; specialty auto products, including motorcycle, trailer, motor home, and off-road vehicle insurance; other personal ...
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ALL vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $922.0M | $708.5M |
| Net Profit | $2.5B | $135.1M |
| Gross Margin | — | — |
| Operating Margin | -1400.3% | 21.6% |
| Net Margin | 266.6% | 19.1% |
| Revenue YoY | 7.2% | 32.0% |
| Net Profit YoY | — | 15.5% |
| EPS (diluted) | $9.25 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $922.0M | — | ||
| Q4 25 | $17.3B | $708.5M | ||
| Q3 25 | $17.3B | $659.9M | ||
| Q2 25 | $16.6B | $603.3M | ||
| Q1 25 | $16.5B | $558.6M | ||
| Q4 24 | $16.5B | $536.6M | ||
| Q3 24 | $16.6B | $533.3M | ||
| Q2 24 | $15.7B | $528.1M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $3.8B | $135.1M | ||
| Q3 25 | $3.7B | $111.1M | ||
| Q2 25 | $2.1B | $90.3M | ||
| Q1 25 | $595.0M | $114.6M | ||
| Q4 24 | $1.9B | $117.0M | ||
| Q3 24 | $1.2B | $96.4M | ||
| Q2 24 | $331.0M | $88.4M |
| Q1 26 | -1400.3% | — | ||
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 21.5% | ||
| Q2 25 | — | 20.9% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | — | 21.1% | ||
| Q2 24 | — | 19.9% |
| Q1 26 | 266.6% | — | ||
| Q4 25 | 22.1% | 19.1% | ||
| Q3 25 | 21.7% | 16.8% | ||
| Q2 25 | 12.7% | 15.0% | ||
| Q1 25 | 3.6% | 20.5% | ||
| Q4 24 | 11.7% | 21.8% | ||
| Q3 24 | 7.2% | 18.1% | ||
| Q2 24 | 2.1% | 16.7% |
| Q1 26 | $9.25 | — | ||
| Q4 25 | $14.24 | $4.65 | ||
| Q3 25 | $13.95 | $3.86 | ||
| Q2 25 | $7.76 | $3.10 | ||
| Q1 25 | $2.11 | $3.67 | ||
| Q4 24 | $7.07 | $3.67 | ||
| Q3 24 | $4.33 | $3.01 | ||
| Q2 24 | $1.13 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.6B | $459.1M |
| Total Assets | $124.0B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | $497.0M | ||
| Q3 25 | $8.7B | $285.4M | ||
| Q2 25 | $9.6B | $46.3M | ||
| Q1 25 | $6.5B | $441.4M | ||
| Q4 24 | $4.5B | $669.4M | ||
| Q3 24 | $7.0B | $656.9M | ||
| Q2 24 | $5.3B | $510.9M |
| Q1 26 | — | — | ||
| Q4 25 | $7.5B | — | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $8.1B | — | ||
| Q1 25 | $8.1B | — | ||
| Q4 24 | $8.1B | — | ||
| Q3 24 | $8.1B | — | ||
| Q2 24 | $8.1B | — |
| Q1 26 | $31.6B | — | ||
| Q4 25 | $30.6B | $459.1M | ||
| Q3 25 | $27.5B | $293.6M | ||
| Q2 25 | $24.0B | $172.4M | ||
| Q1 25 | $22.1B | $593.6M | ||
| Q4 24 | $21.4B | $825.5M | ||
| Q3 24 | $20.9B | $881.4M | ||
| Q2 24 | $18.6B | $763.6M |
| Q1 26 | $124.0B | — | ||
| Q4 25 | $119.8B | $2.0B | ||
| Q3 25 | $120.4B | $1.8B | ||
| Q2 25 | $115.9B | $1.6B | ||
| Q1 25 | $115.2B | $1.9B | ||
| Q4 24 | $111.6B | $2.1B | ||
| Q3 24 | $113.7B | $2.1B | ||
| Q2 24 | $108.4B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.37× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.43× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $192.7M | ||
| Q3 25 | $3.3B | $246.2M | ||
| Q2 25 | $1.9B | $148.5M | ||
| Q1 25 | $2.0B | $125.8M | ||
| Q4 24 | $1.7B | $190.7M | ||
| Q3 24 | $3.2B | $149.1M | ||
| Q2 24 | $2.4B | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | $188.1M | ||
| Q3 25 | $3.2B | $235.5M | ||
| Q2 25 | $1.9B | $142.4M | ||
| Q1 25 | $1.9B | $115.8M | ||
| Q4 24 | $1.7B | $183.0M | ||
| Q3 24 | $3.1B | $138.5M | ||
| Q2 24 | $2.3B | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | 26.6% | ||
| Q3 25 | 18.8% | 35.7% | ||
| Q2 25 | 11.3% | 23.6% | ||
| Q1 25 | 11.4% | 20.7% | ||
| Q4 24 | 10.0% | 34.1% | ||
| Q3 24 | 18.9% | 26.0% | ||
| Q2 24 | 14.7% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 0.6% | ||
| Q3 25 | 0.3% | 1.6% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.6% | 1.8% | ||
| Q4 24 | 0.3% | 1.4% | ||
| Q3 24 | 0.4% | 2.0% | ||
| Q2 24 | 0.4% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.78× | 1.43× | ||
| Q3 25 | 0.88× | 2.22× | ||
| Q2 25 | 0.89× | 1.65× | ||
| Q1 25 | 3.30× | 1.10× | ||
| Q4 24 | 0.88× | 1.63× | ||
| Q3 24 | 2.69× | 1.55× | ||
| Q2 24 | 7.13× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALL
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
